Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Offers Possible Reasons For Vectibix Failure To Show Survival Benefit

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA review documents for Amgen's epidermal growth factor receptor inhibitor Vectibix (panitumumab) outline possible factors that may have led to the biologic's failure to show an overall survival benefit in a pivotal trial.

You may also be interested in...

Case Studies In FDA's Regulatory Interpretation Of Clinical Trials

For more than 15 years, the Pink Sheet's Drug Review Profile series has looked closely at FDA approval documents, providing a long view of the pitfalls and pitches presented in the NEJM series on interpreting clinical trial results.

Approvals In Brief

Genentech Avastin lung cancer claim clears FDA, while Merck’s new molecular entity Zolinza (vorinostat) is approved for cutaneous T-cell lymphoma. Schering-Plough’s novel antifungal Noxafil (posaconazole) is the first treatment cleared for prevention of invasive Aspergillus infection. Genentech/Biogen Idec’s Rituxan (rituximab) gains a third NHL-related claim with approval of two new indications; Johnson & Johnson’s established anti-TNF agent Remicade (infliximab) expands into the dermatology segment with approval for psoriasis. More approvals in brief

Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China

Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts